S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

Detalles Bibliográficos
Autores principales: Mascarenhas, John, Jain, Tania, Otoukesh, Salman, Gerds, Aaron T., Lucchesi, Alessandro, Romina Sosa, Iberia, Laribi, Kamel, Mishchenko, Elena, Radinoff, Atanas, Benevolo, Giulia, Vannucchi, Alessandro M., Boyer, Francoise, Quittet, Philippe, Radsak, Markus, Machet, Antoine, Bose, Prithviraj, Huang, Zhuying, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Passamonti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428378/
http://dx.doi.org/10.1097/01.HS9.0000967752.72578.ff

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428378/
http://dx.doi.org/10.1097/01.HS9.0000967752.72578.ff

Ejemplares similares